CNSX:CRL

Charles River Laboratories International Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume34,000 shs
Average Volume33,785 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Charles River Laboratories International (CNSX:CRL) Vs. AKU, LXG, SQD, SVA, GEN, and LMD

Should you be buying CRL stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Charles River Laboratories International, including Akumin (AKU), LexaGene (LXG), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), and LED Medical Diagnostics (LMD).

Charles River Laboratories International (CNSX:CRL) and Akumin (TSE:AKU) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Charles River Laboratories International and Akumin, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, suggesting a potential upside of 8.70%.

Profitability

This table compares Charles River Laboratories International and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
AkuminN/AN/AN/A

Earnings and Valuation

This table compares Charles River Laboratories International and Akumin's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
AkuminC$246.08 million1.10C$-25,263,475.00C($0.37)-10.71

Charles River Laboratories International has higher earnings, but lower revenue than Akumin.

Summary

Akumin beats Charles River Laboratories International on 2 of the 2 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and LexaGene (CVE:LXG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and target prices for Charles River Laboratories International and LexaGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
LexaGene0000N/A

Profitability

This table compares Charles River Laboratories International and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
LexaGeneN/AN/AN/A

Earnings & Valuation

This table compares Charles River Laboratories International and LexaGene's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
LexaGeneN/AN/AN/AC($0.12)-6.22

Charles River Laboratories International (CNSX:CRL) and SQI Diagnostics (CVE:SQD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Valuation & Earnings

This table compares Charles River Laboratories International and SQI Diagnostics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
SQI DiagnosticsC$977,000.00108.10C$-12,264,984.00C($0.04)-8.61

Charles River Laboratories International has higher earnings, but lower revenue than SQI Diagnostics.

Profitability

This table compares Charles River Laboratories International and SQI Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
SQI DiagnosticsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Charles River Laboratories International and SQI Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
SQI Diagnostics0000N/A

Summary

SQI Diagnostics beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Sernova (CVE:SVA) and Charles River Laboratories International (CNSX:CRL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Sernova and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SernovaN/AN/AN/A
Charles River Laboratories InternationalN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Sernova and Charles River Laboratories International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova0000N/A
Charles River Laboratories International0000N/A

Valuation & Earnings

This table compares Sernova and Charles River Laboratories International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/AN/AC($0.03)-55.19
Charles River Laboratories InternationalN/AN/AN/AN/AN/A

Charles River Laboratories International (CNSX:CRL) and GeneNews (TSE:GEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Charles River Laboratories International and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
GeneNewsN/AN/AN/A

Valuation & Earnings

This table compares Charles River Laboratories International and GeneNews' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

Charles River Laboratories International has higher earnings, but lower revenue than GeneNews.

Analyst Recommendations

This is a breakdown of current ratings for Charles River Laboratories International and GeneNews, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
GeneNews0000N/A

Summary

GeneNews beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and LED Medical Diagnostics (CVE:LMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Charles River Laboratories International and LED Medical Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
LED Medical Diagnostics0000N/A

Profitability

This table compares Charles River Laboratories International and LED Medical Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
LED Medical DiagnosticsN/AN/AN/A

Valuation and Earnings

This table compares Charles River Laboratories International and LED Medical Diagnostics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26

Charles River Laboratories International has higher earnings, but lower revenue than LED Medical Diagnostics.

Summary

LED Medical Diagnostics beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.


Charles River Laboratories International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKU
Akumin
0.7$3.91flatC$270.63 millionC$246.08 million-10.71
LXG
LexaGene
0.5$0.74flatC$83.27 millionN/A-6.22News Coverage
SQD
SQI Diagnostics
0.9$0.31flatC$52.59 millionC$977,000.00-8.61Gap Up
SVA
Sernova
0.5$1.49flatC$31.35 millionN/A-55.19News Coverage
GEN
GeneNews
0.5N/AN/AC$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40flatC$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics
0.6$0.57flatC$5.58 millionC$37,517.00-17.27News Coverage
IDL
Imaging Dynamics
0.4$0.08flatC$4.13 millionC$378,253.00-3.95Gap Down
DXD
3D Signatures
0.5$0.04flatC$2.66 millionN/A-0.91Gap Down
MBI
Med Biogene
0.5$0.05flatC$795,000.00N/A-7.50Gap Up
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.